Bronchodilator reversibility testing in morbidly obese non-smokers : a comparative study- few concerns
© 2024. The Author(s)..
This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.
| Errataetall: |
CommentOn: BMC Pulm Med. 2023 Oct 9;23(1):381. - PMID 37814253 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC pulmonary medicine - 24(2024), 1 vom: 15. März, Seite 132 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Balan, Divya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albuterol |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 19.03.2024 published: Electronic CommentOn: BMC Pulm Med. 2023 Oct 9;23(1):381. - PMID 37814253 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12890-024-02951-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369811860 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369811860 | ||
| 003 | DE-627 | ||
| 005 | 20240319233046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240317s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12890-024-02951-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369811860 | ||
| 035 | |a (NLM)38491503 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Balan, Divya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bronchodilator reversibility testing in morbidly obese non-smokers |b a comparative study- few concerns |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentOn: BMC Pulm Med. 2023 Oct 9;23(1):381. - PMID 37814253 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Albuterol |2 NLM | |
| 650 | 7 | |a QF8SVZ843E |2 NLM | |
| 650 | 7 | |a Fluticasone-Salmeterol Drug Combination |2 NLM | |
| 700 | 1 | |a Shetty, Manish R |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Manu K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d 2001 |g 24(2024), 1 vom: 15. März, Seite 132 |w (DE-627)NLM114960313 |x 1471-2466 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:15 |g month:03 |g pages:132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12890-024-02951-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 15 |c 03 |h 132 | ||